Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 105

1.

Miliary brain metastases in 2 cases with advanced non-small cell lung cancer harboring EGFR mutation during gefitinib treatment.

Mochizuki S, Nishimura N, Inoue A, Murakami K, Nukiwa T, Chohnabayashi N.

Respir Investig. 2012 Sep;50(3):117-21. doi: 10.1016/j.resinv.2012.06.002. Epub 2012 Jul 15.

PMID:
23021771
[PubMed - indexed for MEDLINE]
2.

EGFR mutations in patients with brain metastases from lung cancer: association with the efficacy of gefitinib.

Shimato S, Mitsudomi T, Kosaka T, Yatabe Y, Wakabayashi T, Mizuno M, Nakahara N, Hatano H, Natsume A, Ishii D, Yoshida J.

Neuro Oncol. 2006 Apr;8(2):137-44. Epub 2006 Jan 20.

PMID:
16510849
[PubMed - indexed for MEDLINE]
Free PMC Article
3.

[Antitumor effects of gefitinib for metastatic brain tumors from lung carcinomas with EGFR mutation].

Ono Y, Toyota Y, Toyoshima A, Kuramoto S, Katzumata A, Kawauchi M, Matsumoto Y.

No Shinkei Geka. 2011 Jun;39(6):569-74. Japanese.

PMID:
21628735
[PubMed - indexed for MEDLINE]
4.

Gefitinib therapy in patients with advanced non-small cell lung cancer with or without testing for epidermal growth factor receptor (EGFR) mutations.

Wu JY, Shih JY, Chen KY, Yang CH, Yu CJ, Yang PC.

Medicine (Baltimore). 2011 May;90(3):159-67. doi: 10.1097/MD.0b013e31821a16f4.

PMID:
21512416
[PubMed - indexed for MEDLINE]
5.

Development of central nervous system metastases in patients with advanced non-small cell lung cancer and somatic EGFR mutations treated with gefitinib or erlotinib.

Heon S, Yeap BY, Britt GJ, Costa DB, Rabin MS, Jackman DM, Johnson BE.

Clin Cancer Res. 2010 Dec 1;16(23):5873-82. doi: 10.1158/1078-0432.CCR-10-1588. Epub 2010 Oct 28.

PMID:
21030498
[PubMed - indexed for MEDLINE]
Free PMC Article
6.

Gefitinib alone or with concomitant whole brain radiotherapy for patients with brain metastasis from non-small-cell lung cancer: a retrospective study.

Zeng YD, Zhang L, Liao H, Liang Y, Xu F, Liu JL, Dinglin XX, Chen LK.

Asian Pac J Cancer Prev. 2012;13(3):909-14.

PMID:
22631670
[PubMed - indexed for MEDLINE]
Free Article
7.

Gefitinib or chemotherapy for non-small-cell lung cancer with mutated EGFR.

Maemondo M, Inoue A, Kobayashi K, Sugawara S, Oizumi S, Isobe H, Gemma A, Harada M, Yoshizawa H, Kinoshita I, Fujita Y, Okinaga S, Hirano H, Yoshimori K, Harada T, Ogura T, Ando M, Miyazawa H, Tanaka T, Saijo Y, Hagiwara K, Morita S, Nukiwa T; North-East Japan Study Group.

N Engl J Med. 2010 Jun 24;362(25):2380-8. doi: 10.1056/NEJMoa0909530.

PMID:
20573926
[PubMed - indexed for MEDLINE]
Free Article
8.

Hemorrhage of brain metastasis from non-small cell lung cancer post gefitinib therapy: two case reports and review of the literature.

Yan DF, Yan SX, Yang JS, Wang YX, Sun XL, Liao XB, Liu JQ.

BMC Cancer. 2010 Feb 21;10:49. doi: 10.1186/1471-2407-10-49. Review.

PMID:
20170543
[PubMed - indexed for MEDLINE]
Free PMC Article
9.

Clinical impact of switching to a second EGFR-TKI after a severe AE related to a first EGFR-TKI in EGFR-mutated NSCLC.

Takeda M, Okamoto I, Tsurutani J, Oiso N, Kawada A, Nakagawa K.

Jpn J Clin Oncol. 2012 Jun;42(6):528-33. doi: 10.1093/jjco/hys042. Epub 2012 Mar 28.

PMID:
22457323
[PubMed - indexed for MEDLINE]
Free Article
10.

The impact of initial gefitinib or erlotinib versus chemotherapy on central nervous system progression in advanced non-small cell lung cancer with EGFR mutations.

Heon S, Yeap BY, Lindeman NI, Joshi VA, Butaney M, Britt GJ, Costa DB, Rabin MS, Jackman DM, Johnson BE.

Clin Cancer Res. 2012 Aug 15;18(16):4406-14. doi: 10.1158/1078-0432.CCR-12-0357. Epub 2012 Jun 25.

PMID:
22733536
[PubMed - indexed for MEDLINE]
Free PMC Article
11.

Skin rash and bronchoalveolar histology correlates with clinical benefit in patients treated with gefitinib as a therapy for previously treated advanced or metastatic non-small cell lung cancer.

Dudek AZ, Kmak KL, Koopmeiners J, Keshtgarpour M.

Lung Cancer. 2006 Jan;51(1):89-96. Epub 2005 Nov 14.

PMID:
16290256
[PubMed - indexed for MEDLINE]
12.

Clinical significance of epidermal growth factor receptor gene mutations on treatment outcome after first-line cytotoxic chemotherapy in Japanese patients with non-small cell lung cancer.

Hotta K, Kiura K, Toyooka S, Takigawa N, Soh J, Fujiwara Y, Tabata M, Date H, Tanimoto M.

J Thorac Oncol. 2007 Jul;2(7):632-7.

PMID:
17607119
[PubMed - indexed for MEDLINE]
13.

Gefitinib in patients with brain metastases from non-small-cell lung cancer: a prospective trial.

Ceresoli GL, Cappuzzo F, Gregorc V, Bartolini S, Crinò L, Villa E.

Ann Oncol. 2004 Jul;15(7):1042-7.

PMID:
15205197
[PubMed - indexed for MEDLINE]
Free Article
14.

Clinical outcomes in elderly patients administered gefitinib as first-line treatment in epidermal growth factor receptor-mutated non-small-cell lung cancer: retrospective analysis in a Nagano Lung Cancer Research Group study.

Tateishi K, Ichiyama T, Hirai K, Agatsuma T, Koyama S, Hachiya T, Morozumi N, Shiina T, Koizumi T.

Med Oncol. 2013 Mar;30(1):450. doi: 10.1007/s12032-012-0450-2. Epub 2013 Jan 13.

PMID:
23315220
[PubMed - indexed for MEDLINE]
15.

Efficacy of gefitinib for non-adenocarcinoma non-small-cell lung cancer patients harboring epidermal growth factor receptor mutations: a pooled analysis of published reports.

Shukuya T, Takahashi T, Kaira R, Ono A, Nakamura Y, Tsuya A, Kenmotsu H, Naito T, Kaira K, Murakami H, Endo M, Takahashi K, Yamamoto N.

Cancer Sci. 2011 May;102(5):1032-7. doi: 10.1111/j.1349-7006.2011.01887.x. Epub 2011 Feb 28.

PMID:
21272159
[PubMed - indexed for MEDLINE]
16.

First-line gefitinib in patients with advanced non-small-cell lung cancer harboring somatic EGFR mutations.

Sequist LV, Martins RG, Spigel D, Grunberg SM, Spira A, Jänne PA, Joshi VA, McCollum D, Evans TL, Muzikansky A, Kuhlmann GL, Han M, Goldberg JS, Settleman J, Iafrate AJ, Engelman JA, Haber DA, Johnson BE, Lynch TJ.

J Clin Oncol. 2008 May 20;26(15):2442-9. doi: 10.1200/JCO.2007.14.8494. Epub 2008 May 5. Erratum in: J Clin Oncol. 2008 Jul 10;26(20):3472.

PMID:
18458038
[PubMed - indexed for MEDLINE]
Free Article
17.

[Correlation of epidermal growth factor receptor mutations and HER2/3 protein expression with clinical outcome in advanced non-small cell lung cancer patients treated with gefitinib].

Han Y, Xu JM, Duan HQ, Zhang Y, Liu XQ, Zhang JS.

Chin J Cancer. 2010 Jan;29(1):69-75. Chinese.

PMID:
20038315
[PubMed - indexed for MEDLINE]
Free Article
18.

Combined survival analysis of prospective clinical trials of gefitinib for non-small cell lung cancer with EGFR mutations.

Morita S, Okamoto I, Kobayashi K, Yamazaki K, Asahina H, Inoue A, Hagiwara K, Sunaga N, Yanagitani N, Hida T, Yoshida K, Hirashima T, Yasumoto K, Sugio K, Mitsudomi T, Fukuoka M, Nukiwa T.

Clin Cancer Res. 2009 Jul 1;15(13):4493-8. doi: 10.1158/1078-0432.CCR-09-0391. Epub 2009 Jun 16.

PMID:
19531624
[PubMed - indexed for MEDLINE]
Free Article
19.

Prospective phase II study of gefitinib for chemotherapy-naive patients with advanced non-small-cell lung cancer with epidermal growth factor receptor gene mutations.

Inoue A, Suzuki T, Fukuhara T, Maemondo M, Kimura Y, Morikawa N, Watanabe H, Saijo Y, Nukiwa T.

J Clin Oncol. 2006 Jul 20;24(21):3340-6. Epub 2006 Jun 19.

PMID:
16785471
[PubMed - indexed for MEDLINE]
Free Article
20.

Efficacy of epidermal growth factor receptor tyrosine kinase inhibitors for brain metastasis in non-small cell lung cancer patients harboring either exon 19 or 21 mutation.

Park SJ, Kim HT, Lee DH, Kim KP, Kim SW, Suh C, Lee JS.

Lung Cancer. 2012 Sep;77(3):556-60. doi: 10.1016/j.lungcan.2012.05.092. Epub 2012 Jun 5.

PMID:
22677429
[PubMed - indexed for MEDLINE]
Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk